Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “parvovirus”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 757 records · Page 42Linked to original sources
PubMed1981

[Removal of polio- and parvovirus in sewage-sludge by lime-treatment (author's transl)].

Lime (CaO) applied as conditioner for dewatering municipal sewage sludge in filter-presses is suitable to disinfect sewage sludge with respect to virus. A pH-rise to more than 12 followed by release of ammonia inactivates Polio- and Bovine Parvovirus. Addition of 3 kg CaO and more per m3 of raw sludge inactivates Poliovirus within 30 minutes. 7.5 kg CaO per m3 of anaerobically digested sludge are required to inactivate Polio-virus within 5 days and Bovine Parvovirus within 24 hours. Parvovirus seems to be more sensitive against free ammonia than Poliovirus, but less sensitive against high pH-values.

Calcium↗
PubMed1982

Field evaluation of a canine parvovirus vaccination program, using feline origin modified live virus vaccine.

Antibody titers measured by hemagglutination inhibition testing were determined in previously vaccinated dogs at the time of booster vaccination and 2 weeks later. All vaccines consisted of modified live panleukopenia virus. The booster injection was administered approximately 6 months after the initial parvovirus vaccination series was given. Fecal and serum specimens were collected immediately before and 2 weeks after administration of the booster vaccine for hemagglutination and hemagglutination inhibition testing, respectively. All dogs were privately owned and were from the Columbus, Ohio, area but were from environments with various exposure potentials to canine parvovirus. Results of hemagglutination (HA) testing on feces were negative in all dogs before and after booster vaccination. Therefore, these vaccinations did not interfere with interpretation of HA testing of feces. Results of serum hemagglutination inhibition (HI) testing indicated that 50% of the dogs had serum titers less than 1:80 prior to vaccination and that, of these dogs, 65.2% still had serum titers less than 1:80 2 weeks after the booster vaccination. Only 10.9% of all dogs had a marked increase in serum HI titer after the booster vaccination, indicating that overall serologic response to vaccination was poor. High HI titers (greater than or equal to 1:640) were associated with exposure to other dogs and cats in the neighborhood or to dogs suspected of having had parvovirus infection.

Animals↗
PubMed1982

Development of a modified live, canine origin parvovirus vaccine.

A modified live, canine origin parvovirus vaccine was tested for safety, efficacy, and clinical performance. The vaccine protected dogs from challenge of immunity with canine parvovirus (CPV) that caused clinical illness in all nonvaccinated dogs. Vaccinates all developed CPV serum neutralization antibody titers, with a mean value of 1,664. Challenge virus was not isolated from vaccinates, but feces from nonvaccinated dogs were CPV-positive for up to 4 days following challenge. In a pathogenicity test, dogs inoculated orally with 10 times the label dose remained clinically normal. In a reversion-to-virulence test, the vaccine strain remained nonpathogenic through 6 passages in seronegative test dogs. An immunologic interference test demonstrated that test dogs developed antibodies for all antigens in a combined canine distemper virus-adenovirus 2-parainfluenza virus-parvovirus vaccine and a Leptospira interrogans serovars canicola and icterohaemorrhagiae bacterin. A total of 1,796 doses of the multivalent preparation was administered in a field study, with veterinary practitioners reporting 36 local and 5 generalized reactions.

Animals↗
PubMed1981

Characterization of a parvovirus strain isolated from human adenovirus type 12.

A parvovirus strain was isolated from type 12 human adenovirus. The parvovirus multiplied without helper virus in HEp-2 cell cultures, while its multiplication was enhanced by type 12 and type 18 adenoviruses. Haemagglutinating infective virions as well as soluble haemagglutinins were demonstrated by ultracentrifugation and gel filtration. Virus haemagglutination inhibiting antibodies were found in the sera of healthy rats, whereas sera of healthy persons did not contain antibodies. The parvovirus failed to cause illness in laboratory animals (hamster, mouse, guinea pig).

Adenoviruses, Human↗
PubMed1980

Parvovirus infection in translocated raccoons.

Severe enteritis attributed to parvovirus infection was diagnosed in raccoons (Procyon lotor) purchased from a commercial animal dealer for interstate translocation. Intestinal lesions included edema, hyperemia, and focal mucosal necrosis. Microscopically, intestinal villi were reduced markedly, and there was necrosis of the glandular crypts. Intranuclear inclusions were seen in many crypt cells. A parvovirus that was infective for Crandell feline kidney cells and primary canine kidney cells was isolated from the spleen of a sick raccoon. The raccoon virus was distinguished from feline panleukopenia virus by the former's ability to hemagglutinate swine erythrocytes at a pH of 7.2. Serum neutralization testing of infected raccoons indicated that the raccoon isolate differed from feline panleukopenia virus and may have been canine parvovirus.

Animals↗
PubMed1995

[Rheumatic manifestations of parvovirus B19 infection].

Parvoviruses are small single-strand DNA viruses. Human parvovirus (PV B19) was isolated in the 1970s and recognized as a pathogen in the 80s. Its role was first demonstrated in acute erythroblastopenia in patients with chronic haemolytic anaemia, then in epidemic megalerythema. More recently PVB19 has been shown to be the aetiologic agent in fetal loss and chronic infection in immunodepressed patients. Further attention has focused on rheumatologic manifestations, particularly in prolonged joint diseases raising the problem of differential diagnosis and a possible pathogenic relationship with rheumatoid arthritis and systemic lupus erythematosus. Clinically, subjects with parvovirus B19 infection have flu-like manifestations of joint pain and myalgia lasting for about 1 week. Generally, the joint pain is symmetrical, of inflammatory type usually involving proximal joints (phalangeal joints in two-thirds of the cases). Acute back pain or associated extra-articular signs are often absent. Signs regress spontaneously in 10 to 15 days although longer periods have been observed. Diagnosis can be confirmed by ELISA identification of specific IgM antibodies. Nonsteroid antiinflammatory drugs are generally effective.

Adult↗
PubMed1996

Rheumatic manifestations due to human parvovirus B19. A report of four cases.

Human parvovirus B19 has been incriminated in the genesis of hematologic, dermatologic, neurologic, and rheumatic disorders. We report four cases in which inflammatory rheumatic manifestations developed during the course of human parvovirus B19 infection documented by the presence of IgM and IgG antibodies. There was one case each of monoarthritis, oligoarthritis, polyarthritis, and enthesitis. Three patients had a favorable outcome under nonsteroidal antiinflammatory drug therapy, and one developed reflex sympathetic dystrophy syndrome. In patients with inflammatory rheumatic manifestations that do not fit any specific diagnosis, a careful family history can provide evidence suggesting human parvovirus B19 infection, which should be confirmed by tests for IgM and IgG antibodies.

Adult↗
PubMedDate not supplied

Aplastic anemia due to B19 parvovirus infection in cadaveric renal transplant recipients: an underestimated infectious disease in the immunocompromised host.

Parvovirus B19 has been identified as the etiological agent of "fifth disease" in childhood. It is also a rarely reported cause of anemia in transplanted patients. During a period of 18 months we observed four cases (2 male and 2 female; 53 +/- 4.24 years) of severe aplastic anemia due to parvovirus B19 in kidney transplant patients. The overall incidence of the disease was 6.3% of all our transplanted patients. Symptoms of the disease occurred 22.5 +/- 9.75 days post-operatively. Serum creatinine was 1.5 +/- 0.35 mg/dl. Hb was 6.58 +/- 0.6 g/dl. All patients recovered with 15 days of high doses of commercial immunoglobulins. We conclude that B19 parvovirus infection is probably an underestimated disease in transplant patients. It is a first-period infection, probably donor-transmitted. High dose immunoglobulins are an effective but costly therapy.

Adult↗
PubMed1976

Antibody to porcine, feline and rat parvoviruses in various animal species.

Porcine, feline and rat parvoviruses were shown to be antigenically distinct. Specific antibody to feline and rat parvoviruses was shown in a high proportion of porcine sera, and to the porcine parvovirus in sera from cattle, sheep, cats, guinea-pigs, mice and rats, but not from horse, dog, rabbit, chicken or human.

Animals↗
PubMed2026

Estimating the impact of parvovirus B19 outbreaks on congenital anomalies and fetal outcomes in Wales.

OBJECTIVES: Parvovirus B19 (B19V) is a common infection that can cause complications in pregnancy. Outbreaks of B19V in Europe and the UK were recorded in 2024. We aimed to describe the epidemiology of maternal parvovirus in Wales and to investigate associated fetal outcomes widely and in 2024 specifically. STUDY DESIGN: A retrospective observational study. METHODS: All cases of maternal B19V reported to the Congenital Anomaly Register Information Service (CARIS) were analysed. Maternal risk factors included gestational age at the time of infection and maternal age. Spatio-temporal analysis was performed to look for clusters. Poisson regression was used to model incidence of maternal B19V over time. Fetal outcomes were tested for association with risk factors using linear regression and Fisher's exact test. Outcomes and congenital anomalies were descriptively analysed. RESULTS: Between 1998 and 2025, there were 79 cases of maternal B19V across 81 fetuses, mostly reported in South Wales (74/81, 91.3%). There were 24 (29.6%) cases of at least one confirmed congenital anomaly and 57 (70.3%) cases reporting no anomalies; 53 (93%) of these cases had a positive outcome. Congenital anomalies were associated with worse fetal outcomes. Excluding terminations, the overall fetal survival rate was 88%. No association between maternal risk factors and fetal outcome was identified. There was an increase in cases in 2024 with an increase in fetal losses. CONCLUSIONS: The 2024 European B19V outbreak led to an increase in maternal cases and negative fetal outcomes in Wales.

Humans↗
PubMed1999

Engineering parvovirus-like particles for the induction of B-cell, CD4(+) and CTL responses.

An antigen delivery system based on hybrid recombinant parvovirus-like particles (VLPs) formed by the self-assembly of the capsid VP2 protein of porcine (PPV) or canine parvovirus (CPV) expressed in insect cells with the baculovirus system has been developed. PPV:VLPs containing a CD8(+) epitope from the LCMV nucleoprotein evoked a potent CTL response and were able to protect mice against a lethal infection with the virus. Also, PPV:VLPs containing the C3:T epitope from poliovirus elicited a CD4(+)3 log(10) units) against poliovirus. The possibility of combining different types of epitopes in different positions of a single particle to stimulate different branches of the immune system paves the way to the production of more potent vaccines in a simple and cheap way.

Animals↗
PubMed2001

Parvovirus vectors for human gene therapy.

It has become increasingly clear that parvovirus-based vectors are a potentially safe and useful alternative to the more commonly used retroviral and adenoviral vectors. Parvovirus vectors have been successfully used in phase I clinical trials for gene therapy of cystic fibrosis and hemophilia B, and several salient features of these vectors provide further support to the suggestion that their use in potential gene therapy of a wide variety of human diseases is imminent and perhaps well justified.

Dependovirus↗
PubMedDate not supplied

Risk factors for parvovirus B19 infection in pregnancy.

CONTEXT: Parvovirus B19 infection during pregnancy has been associated with fetal death. However, the incidence of and risk factors for infection in pregnant women have not been well studied. OBJECTIVES: To estimate a pregnant woman's risk of infection with parvovirus B19 in epidemic and endemic situations and to study risk factors for infection. DESIGN: Population-based cohort study conducted between November 1992 and June 1994. SETTING: Three regions in Denmark. PARTICIPANTS: A total of 30946 pregnant women from a consecutive and population-based screening. MAIN OUTCOME MEASURES: Specific IgG antibodies in serum samples obtained in the first trimester of pregnancy and from the newborn infant to assess past infection and seroconversion. Information on family structure, educational background, socioeconomic status, and pregnancy outcome was obtained from national registers. RESULTS: Based on 30 946 serum samples, 65.0% of pregnant women had evidence of past infection. Annual seroconversion rates among susceptible women during endemic and epidemic periods were 1.5% (95% confidence interval [CI], 0.2%-1.9%) and 13.0% (95% CI, 8.7%-23.1 %), respectively. Baseline seropositivity was significantly correlated with increasing number of siblings, having a sibling of the same age, number of own children, and occupational exposure to children. Risk of acute infection increased with the number of children in the household as follows: 0 children odds ratio (OR), 1 (reference); 1 child OR, 3.17 (95% CI, 2.24-4.49); 2 children OR, 5.47 (95% CI, 3.55-8.45); 3 or more children OR, 7.54 (95% CI, 3.80-14.94). Having children aged 6 to 7 years resulted in the highest rate of seroconversion among mothers (6.8%; OR, 4.07; 95% CI, 1.89-8.73). Compared with other pregnant women, nursery school teachers had a 3-fold increased risk of acute infection (OR, 3.09; 95% CI, 1.62-5.89). Population-attributable risk of seroconversion was 55.4% for number of own children and 6.0% for occupational exposure. CONCLUSIONS: The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children. Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.

Acute Disease↗
PubMed1999

Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin--a report of eight patients.

The optimal management of chronic pure red cell aplasia caused by parvovirus B19 (B19-PRCA) in patients with AIDS is unclear. Our purpose was to determine the effects of intravenous immunoglobulin (IVIg) in the treatment of B19-PRCA in patients with AIDS. The patients were eight adults with AIDS admitted during the period 1993-1997. A diagnosis of B19-PRCA was made if all the following criteria were met: 1. Bone marrow biopsy finding of pure red cell aplasia; 2. Detection of parvovirus B19 DNA in serum; and 3. No alternative explanation for PRCA. Initial (induction) therapy was with IVIg 1 g/kg daily for 1-2 days. Relapses were treated with IVIg 1 g/kg for 2 days. Maintenance therapy with IVIg 0.4-1.0 g/kg q 4 weeks was given to those patients who developed a second or subsequent relapse. The patients were followed for a mean of 27 months (range 8-38 months). All patients responded to initial therapy with IVIg. Six patients with CD4 counts < 80 cells/mm3 relapsed. The response was short lived in two patients with a CD4 count < 80 cells/mm3 who were given a single infusion of IVIg 1 g/kg as initial therapy. Four patients were given regular maintenance IVIg therapy following a second or subsequent relapse and remain in remission. Two patients whose CD4 counts were > 300 cells/mm3 remain in continuous unmaintained remission from B19-PRCA for over 8 and 11 months, respectively, following induction therapy with IVIg. AIDS patients with B19-PRCA respond well to therapy with IVIg 2 g/kg given over 2 days. Most patients with CD4 counts of < or = 80 cells/mm3 suffer relapse within six months necessitating retreatment with IVIg; maintenance therapy with IVIg 0.4 g/kg q 4 weeks is effective in preventing relapse of B19-PRCA, and may be cost effective. Routine maintenance therapy is probably not indicated in patients with CD4 counts over 300 cells/mm3. Prospective studies are needed to confirm these findings.

Acquired Immunodeficiency Syndrome↗
PubMed1999

Standardization of a PCR-ELISA in serum samples: diagnosis of active parvovirus B19 infection.

To standardize a PCR assay for the detection of parvovirus B19 DNA in serum samples three different sample treatments were evaluated on the basis of the efficiency of recovery, reproducibility, convenience of sample handling, and presence of PCR inhibitors. Moreover, the presence of an internal standard competitor as the working reagent at one defined concentration in a competitive PCR-ELISA has been suggested as a valid tool to standardize and validate the assay. The results indicated that serum sample treatment by rapid heating fulfilled the criteria for a routine practice in the diagnostic laboratory. Titration experiments carried out to define the optimal amount of the internal standard competitor to use in PCR-ELISA showed that at 2 x10(2) competitor copies, any amplification interferences between target and competitor sequences were avoided. The internal standard competitor in a competitive PCR-ELISA allows the detection of false-negative results due to PCR inhibitors in the samples or large amounts of target DNA. Heating treatment and competitive PCR-ELISA for the detection of parvovirus B19 DNA were applied to the testing of 347 serum samples, which were submitted to the laboratory for B19 investigation. Of the 34 serum samples that were positive for B19 DNA, 15 were from adult patients and 19 from pediatric subjects. B19 infection was associated with haematological disorders, nonimmunological foetal hydrops, atypical rash, arthropathies, hepatic dysfunction, nonspecific symptoms, and congenital infections.

Adolescent↗
PubMed1998

Persistent B19 parvovirus infection in pediatric malignancies.

BACKGROUND AND PROCEDURE: The frequency and clinical importance of parvovirus B19 infection were studied in children investigated or treated for various malignancies and cytopenias. RESULTS: B19 infection was thus demonstrated in six out of 53 unselected children with malignancies by bone marrow examination, using the B19, DNA-specific, polymerase chain reaction (PCR). Examinations using the PCR in serum samples were equally or less sensitive than in bone marrow samples. One of the children had a persistent B19 infection during maintenance therapy for acute lymphoblastic leukemia. She developed a prolonged and severe cytopenia, and the clinical signs included facial rash, chills, high undulating fever, and pharyngitis. She also seroconverted and became B19 IgM-antibody positive during the study period. CONCLUSIONS: Parvovirus B19 infection was detected in 10% of the children and was either asymptomatic or was associated with severe and prolonged cytopenia. Bone marrow examinations are recommended for the detection of B19 DNA in immunosuppressed children.

Adolescent↗
PubMed1999

Pattern of parvovirus B 19 infection during different trimesters of pregnancy in Kuwait.

OBJECTIVE: Aims of this study were to determine the IgG and IgM seropositivity to parvovirus B19 during the three trimesters of pregnancy. METHODS: Initially, a total of 1,047 pregnant women were included in a prospective study. Blood samples were obtained from 343, 406 and 298 cases in the first, second and third trimesters, respectively. To study the incidence of seroconversion, a second sample of blood was obtained 2-4 weeks later from the first 100 cases, who were IgG and IgM negative in the first trimester. RESULTS: The seroprevalence of parvovirus B19 IgG and IgM was 53.3% and 2.2%, respectively. The incidence of seroconversion was 16.5%. The rate of fetal loss was 15.4% in patients with acute infection, all of which occurred in the first two trimesters. CONCLUSIONS: The percentage of IgG positive cases is significantly higher in first and second trimesters compared to the third trimester. The seroconversion rate was 16.5%.

Abortion, Spontaneous↗
PubMed2000

Quantitative direct probe method for the detection of parvovirus B19.

Parvovirus B19 infection is associated with anemia and spontaneous abortions. While many qualitative assays are available, a few molecular-based quantitative methods have been described. This study reports the development and optimization of a quantitative direct-probe method for the detection of Parvovirus B19 DNA. Different concentrations of RNA probes were used to identify the optimal conditions for hybridizing to the target DNA. Detection of DNA was linear between concentrations of 2 ng/ml to 200 pg/ml. Because this method requires no enzymatic amplification, it is not susceptible to amplifier contamination or enzymatic inhibitors, and it can be applied to serum samples or paraffin-embedded tissue.

Adult↗